pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Apr 24·1 min read
save

Daiichi Sankyo postpones annual results, stock dips

Daiichi Sankyo has pushed back the reporting of its annual results, saying it needs more time to finalize the numbers. The Japanese company had intended to unveil its financials for its fiscal year that ended ...

Apr 24, 2026·read at Endpoints ↗

April 24, 2026 05:32 AM EDTUpdated 09:42 AM PharmaManufacturing Dai­ichi Sankyo post­pones an­nu­al re­sults, stock dips Elizabeth Cairns Senior biopharma journalist Dai­ichi Sankyo has pushed back the re­port­ing of its an­nu­al re­sults, say­ing it needs more time to fi­nal­ize the num­bers. The Japan­ese com­pa­ny had in­tend­ed … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

source

Reporting by Endpoints.

read at Endpoints ↗
81 words · retrieved Apr 26
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
DAIICHI SANKYO2

related stories

  • Aug 28Daiichi Sankyo to give commercial team a makeover; Novo Nordisk's GPCR partner finds CMOEndpoints
  • Aug 28Genentech doubles down on ADC-resistant cancers with $1B DualityBio pactFierce Biotech
  • Aug 27Chutes & Ladders—Vivace revs up C-suite ahead of pivotal pushFierce Biotech
  • Aug 26Jazz scores front-line gastric cancer nod from FDA for ‘practice-changing’ ZiiheraBioSpace
  • Aug 10RevMed, BeOne make clinical trial, Asia deal; MoonLake reports Phase 3 winEndpoints